Proton pump inhibitors (PPI) use has been identified as a risk factor for future exacerbations and accelerated decline in FEV1 in children with cystic fibrosis. The findings, from a Dutch longitudinal observational study involving 545 children with CF aged 5-18 years of age, add to previous evidence linking PPIs to an increased risk of respiratory ...
Cystic Fibrosis
PPI use linked to lung disease progression in children with CF
By Michael Woodhead
5 Jul 2018